GBMA welcomes PBS listing of infliximab

The inclusion of the first monoclonal antibody biosimilar on the PBS will deliver immediate savings to the Federal Government; however the full potential of this and other biosimilar medicines relies on market uptake drivers aimed at prescribers, pharmacists and patients, says the Generic and Biosimilar Medicines Association. GBMA welcomed today’s PBS listing of Inflectra (infliximab)